Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists

Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists

Background. Given the proven excessive activation of the renin-angiotensin-aldosterone system and the clinical manifestations of hypertension, mostly of renal origin, there is a need to optimize antihypertensive therapy aimed at an active nephroprotection. The purpose of the study is to carry out a...

Full description

Bibliographic Details
Main Authors:	V.М. Yerokhovych, Y.I. Komisarenko, O.V. Karpenko, V.I. Pankiv, N.M. Kobyliak, M.I. Bobryk, D.V. Kyriienko, K.S. Gurska, A.A. Kaplina, V.L. Vasiuk
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2023-12-01
Series:	Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:	diabetes mellitus chronic kidney disease hypertension primary hyperaldosteronism mineralocorticoid receptor antagonists
Online Access:	https://iej.zaslavsky.com.ua/index.php/journal/article/view/1341

Similar Items

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Molecular Mechanisms of Primary Aldosteronism
by: Sergei G. Tevosian, et al.
Published: (2019-12-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019-12-01)

Adverse Effects of Aldosterone: Beyond Blood Pressure
by: Jenifer M. Brown
Published: (2024-04-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Daiji Kawanami, et al.
Published: (2021-10-01)

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
by: Eqerem Hasani, et al.
Published: (2022-01-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
by: Shuhui Zhai, et al.
Published: (2024-09-01)

Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism
by: Yu-Fang Lin, et al.
Published: (2020-12-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Demystifying “steroid withdrawal” during remission in Cushing's disease: Is mineralocorticoid replacement the answer?
by: Nimisha Jain, et al.
Published: (2019-01-01)

Influence of Different Treatment Strategies on New‐Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort‐Based Study
by: Chien‐Ting Pan, et al.
Published: (2020-03-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
by: Mary Elizabeth Moss, et al.
Published: (2015-09-01)

New Perspectives on Sex Steroid and Mineralocorticoid Receptor Signaling in Cardiac Ischemic Injury
by: Laura A. Bienvenu, et al.
Published: (2022-06-01)

Comentario. Mineralocorticoides: Una vida para su investigación.
by: Alfredo Jácome Roca
Published: (2001-08-01)

Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study
by: Yen Kheng Tan, et al.
Published: (2021-07-01)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
by: Natalia V. Safronova, et al.
Published: (2022-01-01)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
by: Jason M. Duran, et al.
Published: (2020-04-01)

case of liquorice-infused marijuana causing syndrome of apparent mineralocorticoid excess
by: Asnia Latif, et al.
Published: (2023-08-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
by: Irina N. Bobkova
Published: (2023-11-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease
by: Andrei Niculae, et al.
Published: (2022-03-01)

Early diagnosis of mineral and bone disorders in patients with diabetic kidney disease on the background of type 2 diabetes
by: V.M. Yerokhovych, et al.
Published: (2024-06-01)

Research progress on the effects of mineralocorticoid receptor on cardiovascular diseases
by: MA Qian-yu, PENG Shi, ZHANG Zhao-yuan, ZHANG Dan, ZHANG Jin
Published: (2022-08-01)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
by: Frédéric Jaisser, et al.
Published: (2021-06-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex
by: Naoto Kuyama, et al.
Published: (2024-09-01)

Familial Mineralocorticoid Induced Hypertension in the Sultanate of Oman
by: Nicholas JY Woodhouse, et al.
Published: (2008-07-01)

The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice
by: Stefanny M. Figueroa, et al.
Published: (2023-04-01)

Regulación de la acción de la Aldosterona al nivel del receptor mineralocorticoide
by: Roberto Franco Saenz
Published: (2001-08-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
by: Josefin Henrysson, et al.
Published: (2023-02-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
by: Ulrich Kintscher, et al.
Published: (2023-06-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013-10-01)

A case of pseudohypoaldosteronism type 1 with a mutation in the mineralocorticoid receptor gene
by: Se Eun Lee, et al.
Published: (2011-02-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)

The problem of timely diagnosis of primary hyperaldosteronism. Clinical case
by: V.M. Zhdan, et al.
Published: (2023-10-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)